I went to the actual paper the above interpreted:Novel Technology Could Prevent Repeat Operations to Replace a Faulty Bioprosthetic Heart Valve
![]()
Novel Technology Could Prevent Repeat Operations to Replace a Faulty Bioprosthetic Heart Valve
March 2, 2022 – An international study led by a researcher from Tel Aviv University offers a novel technology that can assist many patients implanted with bioprosthetic heart valve by avoiding additional complicated replacement surgery. Many heart patients implanted with such valves are forced...www.dicardiology.com

The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration - Nature Medicine
In a large cohort of patients who underwent aortic valve replacement, antibody responses to glycans present in bioprosthetic heart valves, notably galactose-α1,3-galactose and N-glycolylneuraminic acid, were implicated in valve calcification and deterioration.

Moreover, in mice, anti-Neu5Gc antibodies were unable to promote calcium deposition on subcutaneously implanted BHV tissue engineered to lack αGal and Neu5Gc antigens. These results indicate that BHVs manufactured using donor tissues deficient in αGal and Neu5Gc could be less prone to immune-mediated deterioration and have improved durability.
Somehow more realistic claims...